LIVIVO - Search results -

Search results

Result 1 - 10 of total 71

Search options

Book ; Online ; E-Book: 2024 Nelson's Pediatric Antimicrobial Therapy

Bradley, John S. / Nelson, John D. / Elizabeth, Barnett / Cantey, Joseph B. / Kimberlin, David W. / Palumbo, Paul E. / Sauberan, Jason / Smart, J. Howard / Steinbach, William J.

2024

Abstract: Completely updated and revised, the 30th edition of this best-selling reference provides instant access to the latest recommendations for treatment of infectious diseases in children. For each disease, the authors provide a commentary to help select ... ...

Abstract	Completely updated and revised, the 30th edition of this best-selling reference provides instant access to the latest recommendations for treatment of infectious diseases in children. For each disease, the authors provide a commentary to help select the best of all antimicrobial choices. Drug descriptions cover all antimicrobial agents available today and include complete information about dosing regimens. Free updates available at aap.org/Nelsons.
Language	English
Size	1 online resource (403 pages)
Edition	30th ed.
Publisher	American Academy of Pediatrics
Publishing place	Elk Grove Village
Document type	Book ; Online ; E-Book
Remark	Zugriff für angemeldete ZB MED-Nutzerinnen und -Nutzer
ISBN	1-61002-697-7 ; 9781610026963 ; 978-1-61002-697-0 ; 1610026969
Database	ZB MED Catalogue: Medicine, Health, Nutrition, Environment, Agriculture

Full text online

Accessible to users with ZB MED library card

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾
- Full text online
- Order with fees

Book ; Online ; E-Book: Nelson's neonatal antimicrobial therapy

Cantey, Joseph B. / Nelson, John D. / Elizabeth, Barnett / Bradley, John S. / Kimberlin, David W. / Palumbo, Paul E. / Smart, J. Howard / Steinbach, William J. / Sauberan, Jason

2024

Abstract: Completely updated and revised, Nelson's Neonatal Antimicrobial Therapy, 2nd Edition, provides the most current, practical, and evidence-based recommendations for health care professionals treating neonates. Developed by leading experts in antimicrobial ... ...

Title variant	Neonatal antimicrobial therapy
Institution	American Academy of Pediatrics
Author's details	Joseph B. Cantey, MD, MPH, Jason Sauberan, PharmD Editors in Chief, John D. Nelson, Emeritus
Abstract	Completely updated and revised, Nelson's Neonatal Antimicrobial Therapy, 2nd Edition, provides the most current, practical, and evidence-based recommendations for health care professionals treating neonates. Developed by leading experts in antimicrobial therapy, this resource aims to help clinicians select the right drug, dose, and duration for the treatment of bacterial, viral, fungal, and parasitic infections in neonates. Front Matter -- 1. Choosing an Antibiotic for the Neonate -- 2. Antimicrobial Drug Therapy for Neonates -- 3. Bacterial Infections in Neonates -- 4. Viral Infections in Neonates -- 5. Fungal Infections in Neonates -- 6. Parasitic Infections in Neonates -- 7. Antimicrobial Stewardship in the Nursery -- Index.
Subject code	618.9201
Language	English
Size	1 Online-Ressource (x, 92 Seiten)
Edition	Second edition
Publisher	American Academy of Pediatrics
Publishing place	Elk Grove Village
Publishing country	United States
Document type	Book ; Online ; E-Book
Note	Description based on publisher supplied metadata and other sources
Remark	Zugriff für angemeldete ZB MED-Nutzerinnen und -Nutzer
HBZ-ID	HT030696544
ISBN	978-1-61002-699-4 ; 9781610026987 ; 1-61002-699-3 ; 1610026985
Database	ZB MED Catalogue: Medicine, Health, Nutrition, Environment, Agriculture

Full text online

Accessible to users with ZB MED library card

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾
- Full text online
- Order with fees

Article ; Online: February 2024 ACIP Meeting Update: Meningococcal, RSV, COVID-19, and Other Vaccines.

Gaviria-Agudelo, Claudia / Yonts, Alexandra B / Kimberlin, David W / Campbell, James D / Paulsen, Grant C / O'Leary, Sean T

Pediatrics

2024

Abstract: The Advisory Committee on Immunization Practices (ACIP), a group of medical and public health experts that provides advice to the Centers for Disease Control and Prevention, normally meets 3 times per year to develop US vaccine recommendations. The ACIP ... ...

Abstract	The Advisory Committee on Immunization Practices (ACIP), a group of medical and public health experts that provides advice to the Centers for Disease Control and Prevention, normally meets 3 times per year to develop US vaccine recommendations. The ACIP met February 28 to 29, 2024, to discuss coronavirus disease (COVID-19) vaccines, chikungunya vaccines, DT vaccine, influenza vaccines, polio vaccines, RSV vaccines, meningococcal vaccines, pneumococcal vaccines and Vaxelis (DTaP, Inactivated Poliovirus, Haemophilus influenzae b Conjugate & Hepatitis B Vaccine). This update summarizes the proceedings of these meetings, with an emphasis on topics that are most relevant to the pediatric population. Major updates for pediatric clinicians include information about changes on influenza vaccine composition, meningococcal vaccination considerations, updated guidance for children with a contraindication to pertussis-containing vaccines, and recommendations of the world's first chikungunya vaccine for certain populations.
Language	English
Publishing date	2024-03-29
Publishing country	United States
Document type	Journal Article
ZDB-ID	207677-9
ISSN	1098-4275 ; 0031-4005
ISSN (online)	1098-4275
ISSN	0031-4005
DOI	10.1542/peds.2024-066653
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Um IV Zs.131: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MO 357: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Impact of human coronavirus infections on paediatric patients at a tertiary paediatric hospital: a retrospective study of the prepandemic era.

Alsulami, A O / Chahine, R / Kong, M / Kimberlin, D W / Whitley, R J / James, S H

The Journal of hospital infection

2023 Volume 134, Page(s) 27–34

Abstract: Background: Human coronaviruses (HCoVs) are important respiratory pathogens in humans and animals. Most HCoVs are emerging pathogens, with five known human pathogens identified in the last two decades.: Aim: To examine the clinical course of HCoV ... ...

Abstract	Background: Human coronaviruses (HCoVs) are important respiratory pathogens in humans and animals. Most HCoVs are emerging pathogens, with five known human pathogens identified in the last two decades. Aim: To examine the clinical course of HCoV infection in children to improve understanding of severity and outcomes. Methods: A retrospective review was undertaken of all encounters of children with known HCoV infection at a tertiary paediatric hospital from January 2015 to January 2018. Electronic medical records were reviewed for demographic data, HCoV type, viral co-pathogens, time to testing, need for hospitalization, requirement for higher-level care (HLC) including intensive care unit management and requirement for oxygen support, radiographic findings suggestive of lower respiratory tract (LRT) disease, and length of stay (LOS). Findings: In total, 450 encounters for 430 different patients were identified, with the majority (85%) being inpatient. OC43 was the most common HCoV. Younger patients (age <5 years) had higher probability of hospitalization [adjusted odds ratio (aOR) 2.2, 95% confidence interval (CI) 1.2-4.1], requirement for HLC (aOR 1.8, 95% CI 1.0-3.1) and presence of LRT findings on chest radiographs (aOR 1.7, 95% CI 1.01-2.9). Clinical outcomes did not differ between HCoV types, except LOS which was longer for 229E. Fifty-two (11%) encounters were detected after 3 days of hospitalization (median 25.5 days), suggesting possible nosocomial infection. Conclusion: HCoVs are important respiratory pathogens in the paediatric population, especially among patients aged <5 years who are at increased risk for severe disease. The role of HCoVs as hospital-acquired pathogens may be underappreciated.
MeSH term(s)	Child ; Humans ; Retrospective Studies ; Coronavirus Infections/epidemiology ; Coronavirus Infections/prevention & control ; Hospitals, Pediatric ; Respiratory Tract Infections/epidemiology ; Inpatients
Language	English
Publishing date	2023-01-19
Publishing country	England
Document type	Journal Article
ZDB-ID	779366-2
ISSN	1532-2939 ; 0195-6701
ISSN (online)	1532-2939
ISSN	0195-6701
DOI	10.1016/j.jhin.2022.12.021
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1586: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Screening for Congenital Cytomegalovirus After Newborn Hearing Screening: What Comes Next?

Grosse, Scott D / Dollard, Sheila C / Kimberlin, David W

Pediatrics

2017 Volume 139, Issue 2

MeSH term(s)	Cytomegalovirus ; Cytomegalovirus Infections/congenital ; Hearing Loss, Sensorineural ; Humans ; Infant, Newborn ; Neonatal Screening
Language	English
Publishing date	2017
Publishing country	United States
Document type	Journal Article ; Comment
ZDB-ID	207677-9
ISSN	1098-4275 ; 0031-4005
ISSN (online)	1098-4275
ISSN	0031-4005
DOI	10.1542/peds.2016-3837
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Um IV Zs.131: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MO 357: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Update from the Advisory Committee on Immunization Practices.

O'Leary, Sean T / Maldonado, Yvonne A / Kimberlin, David W

Journal of the Pediatric Infectious Diseases Society

2020 Volume 9, Issue 1, Page(s) 3–5

Abstract: ... of Pediatrics (Y. A. M., D. W. K.) and the Pediatric Infectious Diseases Society (S. T. O.) are present ...

Abstract	The Advisory Committee on Immunization Practices (ACIP), a group of medical and public health experts, meets 3 times per year to develop recommendations for vaccine use in the United States. There are usually 15 voting members; members' terms are for 4 years. ACIP members and Centers for Disease Control and Prevention staff discuss the epidemiology of vaccine-preventable diseases and vaccine research, effectiveness, safety data, and results from clinical trials. Representatives from the American Academy of Pediatrics (Y. A. M., D. W. K.) and the Pediatric Infectious Diseases Society (S. T. O.) are present as liaisons to the ACIP. The ACIP met on 23-24 October 2019 to discuss pertussis vaccines, the child/adolescent and adult immunization schedule, influenza vaccine effectiveness and safety, Ebola vaccine, orthopoxvirus vaccines, Dengue vaccine, rabies vaccine, measles, and vaccine safety update.
MeSH term(s)	Advisory Committees ; Humans ; Immunization/standards ; Immunization Schedule ; Practice Guidelines as Topic ; Viral Vaccines/administration & dosage ; Viral Vaccines/adverse effects
Chemical Substances	Viral Vaccines
Language	English
Publishing date	2020-02-03
Publishing country	England
Document type	Congress
ZDB-ID	2668791-4
ISSN	2048-7207 ; 2048-7193
ISSN (online)	2048-7207
ISSN	2048-7193
DOI	10.1093/jpids/piaa008
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Update From the Advisory Committee on Immunization Practices.

O Leary, Sean T / Maldonado, Yvonne A / Kimberlin, David W

Journal of the Pediatric Infectious Diseases Society

2020 Volume 9, Issue 6, Page(s) 645–649

Abstract: ... Academy of Pediatrics (Y. A. M. and D. W. K.) and the Pediatric Infectious Diseases Society (S. T. O.) are ...

Abstract	The Advisory Committee on Immunization Practices (ACIP), a group of medical and public health experts, normally meets 3 times per year to develop recommendations for vaccine use in the United States. Because of the severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) pandemic, there are several SARS-CoV-2 vaccines currently in late-stage clinical trials, so the ACIP is now meeting monthly for single day meetings, with plans to continue standard 2- to 3-day meetings as per usual (February, June, and October). Emergency meetings of ACIP may occur if a vaccine candidate receives an Emergency Use Authorization from the food and drug administration (FDA). This Update provides a combined summary of the August 26 and September 22, 2020, meetings, both of which focused completely on Coronavirus disease 2019 (COVID-19) vaccines. The representatives from the American Academy of Pediatrics (Y. A. M. and D. W. K.) and the Pediatric Infectious Diseases Society (S. T. O.) are present as liaisons to the ACIP.
MeSH term(s)	Advisory Committees ; COVID-19/prevention & control ; COVID-19 Vaccines/standards ; COVID-19 Vaccines/therapeutic use ; Humans ; SARS-CoV-2/immunology ; United States
Chemical Substances	COVID-19 Vaccines
Keywords	covid19
Language	English
Publishing date	2020-11-12
Publishing country	England
Document type	Journal Article
ZDB-ID	2668791-4
ISSN	2048-7207 ; 2048-7193
ISSN (online)	2048-7207
ISSN	2048-7193
DOI	10.1093/jpids/piaa144
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Update From the Advisory Committee on Immunization Practices.

O'Leary, Sean T / Campbell, James D / Kimberlin, David W

Journal of the Pediatric Infectious Diseases Society

2018 Volume 7, Issue 4, Page(s) 270–274

Abstract: ... J. D. C. and D. W. K.) and the Pediatric Infectious Diseases Society (S. T. O.) are present ...

Abstract	The Advisory Committee on Immunization Practices (ACIP), a group of medical and public health experts, meets 3 times per year to develop recommendations for vaccine use in the United States. The group has 15 voting members, and each member's term is 4 years. ACIP members and Centers for Disease Control and Prevention staff discuss the epidemiology of vaccine-preventable diseases and vaccine research, effectiveness, safety data, and clinical trial results. Representatives from the American Academy of Pediatrics (J. D. C. and D. W. K.) and the Pediatric Infectious Diseases Society (S. T. O.) are present as liaisons to the ACIP. The ACIP met on June 20 and 21, 2018, to discuss influenza vaccine effectiveness and safety, anthrax vaccination in the setting of a mass exposure, human papillomavirus vaccine, mumps vaccine, Japanese encephalitis vaccine, and pneumococcal vaccination among adults.
MeSH term(s)	Adolescent ; Adult ; Advisory Committees ; Aged ; Anthrax Vaccines/administration & dosage ; Anthrax Vaccines/adverse effects ; Anthrax Vaccines/supply & distribution ; Child ; Child, Preschool ; Humans ; Immunization Schedule ; Infant ; Influenza Vaccines/adverse effects ; Influenza Vaccines/therapeutic use ; Japanese Encephalitis Vaccines/adverse effects ; Japanese Encephalitis Vaccines/therapeutic use ; Middle Aged ; Mumps Vaccine/therapeutic use ; Papillomavirus Vaccines/therapeutic use ; Pneumococcal Vaccines/adverse effects ; Pneumococcal Vaccines/therapeutic use ; Vaccination/adverse effects ; Vaccination/standards ; Vaccines/adverse effects ; Vaccines/standards ; Vaccines/therapeutic use ; Young Adult
Chemical Substances	Anthrax Vaccines ; Influenza Vaccines ; Japanese Encephalitis Vaccines ; Mumps Vaccine ; Papillomavirus Vaccines ; Pneumococcal Vaccines ; Vaccines
Language	English
Publishing date	2018-08-16
Publishing country	England
Document type	Journal Article ; Practice Guideline
ZDB-ID	2668791-4
ISSN	2048-7207 ; 2048-7193
ISSN (online)	2048-7207
ISSN	2048-7193
DOI	10.1093/jpids/piy070
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Variation in Diagnostic Testing and Empiric Acyclovir Use for HSV Infection in Febrile Infants.

Treasure, Jennifer D / Shah, Samir S / Hall, Matt / Mahant, Sanjay / Berry, Jay G / Kimberlin, David W / Schondelmeyer, Amanda C

Hospital pediatrics

2021 Volume 11, Issue 9, Page(s) 922–930

Abstract: Background and objectives: Clinicians evaluating for herpes simplex virus (HSV) in febrile infants must balance detection with overtesting, and there is no universally accepted approach to risk stratification. We aimed to describe variation in ... ...

Abstract	Background and objectives: Clinicians evaluating for herpes simplex virus (HSV) in febrile infants must balance detection with overtesting, and there is no universally accepted approach to risk stratification. We aimed to describe variation in diagnostic evaluation and empirical acyclovir treatment of infants aged 0 to 60 days presenting with fever and determine the association between testing and length of stay (LOS). Methods: In this retrospective 44-hospital observational study, we used the Pediatric Health Information System database to identify infants aged ≤60 days evaluated for fever in emergency departments from January 2016 through December 2017. We described hospital-level variation in laboratory testing, including HSV, imaging and other diagnostic evaluations, acyclovir use, and LOS. We assessed the relationship between HSV testing and LOS using generalized linear mixed effects models adjusted for age and illness severity. Results: In 24 535 encounters for fever, the median HSV testing frequency across hospitals was 35.6% (interquartile range [IQR]: 28.5%-53.5%) for infants aged 0 to 21 days and 12% (IQR: 8.6%-15.7%) for infants aged 22 to 60 days. Among HSV-tested patients, median acyclovir use across hospitals was 79.2% (IQR: 68.1%-89.7%) for those aged 0 to 21 days and 63.6% (IQR: 44.1%-73%) for those aged 22 to 60 days. The prevalence of additional testing varied substantially by hospital and age group. Risk-adjusted LOS for HSV-tested infants was significantly longer than risk-adjusted LOS for those not tested (2.6 vs 1.9 days, Conclusions: Substantial variation exists in diagnostic evaluation and acyclovir use, and infants who received HSV testing had a longer LOS than infants who did not. This variability supports the need for further studies to help clinicians better risk-stratify febrile infants and to guide HSV testing and treatment decisions.
MeSH term(s)	Acyclovir/therapeutic use ; Child ; Diagnostic Tests, Routine ; Herpes Simplex/diagnosis ; Herpes Simplex/drug therapy ; Herpes Simplex/epidemiology ; Humans ; Infant ; Retrospective Studies ; Simplexvirus
Chemical Substances	Acyclovir (X4HES1O11F)
Language	English
Publishing date	2021-08-16
Publishing country	United States
Document type	Journal Article ; Observational Study ; Research Support, U.S. Gov't, P.H.S.
ISSN	2154-1671
ISSN (online)	2154-1671
DOI	10.1542/hpeds.2020-003129
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Remdesivir for COVID-19 in Hospitalized Children: A Phase 2/3 Study.

Ahmed, Amina / Munoz, Flor M / Muller, William J / Agwu, Allison / Kimberlin, David W / Galli, Luisa / Deville, Jaime G / Sue, Paul K / Mendez-Echevarria, Ana / Humeniuk, Rita / Guo, Susan / Rodriguez, Lauren / Han, Dong / Hedskog, Charlotte / Maxwell, Heather / Palaparthy, Ramesh / Kersey, Kathryn / Rojo, Pablo

Pediatrics

2024 Volume 153, Issue 3

Abstract: Objectives: Remdesivir decreases the risk of SARS-CoV-2 infection progressing to severe disease in adults. This study evaluated remdesivir safety and pharmacokinetics in infants and children.: Methods: This was a phase 2/3, open-label trial in ... ...

Abstract	Objectives: Remdesivir decreases the risk of SARS-CoV-2 infection progressing to severe disease in adults. This study evaluated remdesivir safety and pharmacokinetics in infants and children. Methods: This was a phase 2/3, open-label trial in children aged 28 days to 17 years hospitalized for polymerase chain reaction-confirmed SARS-CoV-2 infection. Participants received for ≤10 days once-daily intravenous remdesivir doses defined using physiologically based pharmacokinetic modeling (for ≥40 kg, 200 mg day 1, then 100 mg/day; for age ≥28 days and ≥3 to <40 kg, 5 mg/kg day 1, then 2.5 mg/kg/day). Sparse pharmacokinetic samples were analyzed using population-pharmacokinetic approaches for remdesivir and metabolites GS-704277 and GS-441524. Results: Among 53 participants, at enrollment the median (Q1, Q3) number of days of COVID-19 symptoms was 5 (3, 7) and hospitalization was 1 (1, 3). Underlying conditions included obesity in 19 (37%), asthma in 11 (21%), and cardiac disorders in 11 (21%). Median duration of remdesivir treatment was 5 days (range, 1-10). Remdesivir treatment had no new apparent safety trends. Two participants discontinued treatment because of adverse events including elevated transaminases; both had elevated transaminases at baseline. Three deaths occurred during treatment (and 1 after). When compared with phase 3 adult data, estimated mean pediatric parameters (area under the concentration-time curve over 1 dosing interval, AUCτ, Cmax, and Cτ) were largely overlapping but modestly increased (remdesivir, 33%-129%; GS-704277, 37%-124%; GS-441524, 0%-60%). Recovery occurred for 62% of participants on day 10 and 83% at last assessment. Conclusions: In infants and children with COVID-19, the doses of remdesivir evaluated provided drug exposure similar to adult dosing. In this study with a small sample size, no new safety concerns were observed.
MeSH term(s)	Adult ; Infant ; Humans ; Child ; Child, Hospitalized ; COVID-19 ; COVID-19 Drug Treatment ; SARS-CoV-2 ; Pyrroles ; Transaminases ; Adenosine Monophosphate/analogs & derivatives ; Alanine/analogs & derivatives
Chemical Substances	remdesivir (3QKI37EEHE) ; Pyrroles ; Transaminases (EC 2.6.1.-) ; Adenosine Monophosphate (415SHH325A) ; Alanine (OF5P57N2ZX)
Language	English
Publishing date	2024-03-04
Publishing country	United States
Document type	Clinical Trial, Phase III ; Clinical Trial, Phase II ; Journal Article
ZDB-ID	207677-9
ISSN	1098-4275 ; 0031-4005
ISSN (online)	1098-4275
ISSN	0031-4005
DOI	10.1542/peds.2023-063775
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Um IV Zs.131: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MO 357: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

Full text online

Kategorien

Order via subito

Inter-library loan at ZB MED

Full text online

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito